• Je něco špatně v tomto záznamu ?

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

D. Belada, P. Georgiev, S. Dakhil, LF. Inhorn, D. Andorsky, JT. Beck, D. Quick, R. Pettengell, R. Daly, JP. Dean, M. Pavlyuk, N. Failloux, K. Hübel,

. 2016 ; 12 (15) : 1759-68. [pub] 20160420

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013939
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2005-02-01 do 2020-12-31
Health & Medicine (ProQuest) od 2005-02-01 do 2020-12-31

Odkazy

PubMed 27093976
DOI 10.2217/fon-2016-0137
Knihovny.cz E-zdroje

UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. TRIAL REGISTRATION NUMBER: NCT01321541.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013939
003      
CZ-PrNML
005      
20240313100227.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2016-0137 $2 doi
035    __
$a (PubMed)27093976
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Belada, David $u 4th Department of Internal Medicine - Hematology, Charles University Hospital & Faculty of Medicine, Hradec Králové, Czech Republic.
245    10
$a Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma / $c D. Belada, P. Georgiev, S. Dakhil, LF. Inhorn, D. Andorsky, JT. Beck, D. Quick, R. Pettengell, R. Daly, JP. Dean, M. Pavlyuk, N. Failloux, K. Hübel,
520    9_
$a UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. TRIAL REGISTRATION NUMBER: NCT01321541.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a deoxycytidin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D003841
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a isochinoliny $x aplikace a dávkování $x škodlivé účinky $7 D007546
650    _2
$a nehodgkinský lymfom $x farmakoterapie $7 D008228
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Georgiev, Pencho $u UMHAT "Sveti Georgi", Plovdiv, Clinical Haematology Clinic, Plovdiv, Bulgaria.
700    1_
$a Dakhil, Shaker $u Cancer Center of Kansas, Wichita, KS, USA.
700    1_
$a Inhorn, Lowell F $u Blue Ridge Cancer Care, Roanoke, VA, USA.
700    1_
$a Andorsky, David $u Rocky Mountain Cancer Center, Boulder, CO, USA. $7 gn_A_00006267
700    1_
$a Beck, J Thaddeus $u Highlands Oncology Group, Fayetteville, AR, USA.
700    1_
$a Quick, Donald $u Joe Arrington Cancer Research & Treatment Center, Lubbock, TX, USA.
700    1_
$a Pettengell, R. $u St George's Healthcare NHS Trust, Tooting, London, UK. $7 xx0314847
700    1_
$a Daly, Robert $u CTI Biopharma Corp., Seattle, WA, USA.
700    1_
$a Dean, James P $u CTI Biopharma Corp., Seattle, WA, USA.
700    1_
$a Pavlyuk, Mariya $u Institut de Recherches Internationales Servier, Suresnes, France.
700    1_
$a Failloux, Nelly $u Institut de Recherches Internationales Servier, Suresnes, France.
700    1_
$a Hübel, Kai $u University Hospital of Cologne, Cologne, Germany.
773    0_
$w MED00008687 $t Future oncology $x 1744-8301 $g Roč. 12, č. 15 (2016), s. 1759-68
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27093976 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20240313100222 $b ABA008
999    __
$a ok $b bmc $g 1200404 $s 974717
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 12 $c 15 $d 1759-68 $e 20160420 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace